BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16193303)

  • 1. Decitabine activates specific caspases downstream of p73 in myeloid leukemia.
    Tamm I; Wagner M; Schmelz K
    Ann Hematol; 2005 Dec; 84 Suppl 1():47-53. PubMed ID: 16193303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
    Schmelz K; Wagner M; Dörken B; Tamm I
    Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
    Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X
    Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aza-2'-deoxycytidine increases the sensitivity of human bone marrow mesenchymal stem cells to chemotherapeutic agents by demethylation of p73.
    Liang W; Xia H; Li J; Chunhua Zhao R
    J Pediatr Hematol Oncol; 2012 Mar; 34(2):108-15. PubMed ID: 22278203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
    Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
    Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
    Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2'-deoxycytidine (Decitabine).
    Farinha NJ; Shaker S; Lemaire M; Momparler L; Bernstein M; Momparler RL
    Anticancer Res; 2004; 24(1):75-8. PubMed ID: 15015578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.
    Steinhart L; Belz K; Fulda S
    Cell Death Dis; 2013 Sep; 4(9):e802. PubMed ID: 24030154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
    Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
    Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway.
    Lavelle D; DeSimone J; Hankewych M; Kousnetzova T; Chen YH
    Leuk Res; 2003 Nov; 27(11):999-1007. PubMed ID: 12859993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia.
    Soncini M; Santoro F; Gutierrez A; Frigè G; Romanenghi M; Botrugno OA; Pallavicini I; Pelicci P; Di Croce L; Minucci S
    Biochim Biophys Acta; 2013 Jan; 1832(1):114-20. PubMed ID: 23046813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.
    Agrawal S; Hofmann WK; Tidow N; Ehrich M; van den Boom D; Koschmieder S; Berdel WE; Serve H; Müller-Tidow C
    Blood; 2007 May; 109(9):3895-905. PubMed ID: 17234736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
    Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
    Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
    Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
    PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
    Du Y; Lu F; Li P; Ye J; Ji M; Ma D; Ji C
    Int J Mol Sci; 2014 Sep; 15(9):17065-76. PubMed ID: 25257528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
    Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
    Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.
    Lindsey JC; Lusher ME; Anderton JA; Bailey S; Gilbertson RJ; Pearson AD; Ellison DW; Clifford SC
    Carcinogenesis; 2004 May; 25(5):661-8. PubMed ID: 14688019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.